Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenofibrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 7/20 | 1.00 |
| ▸ | CNR1 | P21554 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | PPARG | P37231 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenofibrate SCHEMBL4670 | 1.00 | PPARA (1.00) | PPARACNR1CYP1A2CYP3A4PPARG | |
| Fenofibrate SCHEMBL29262792 | 0.99 | PPARA (0.97) | PPARACNR1CYP1A2CYP3A4PPARG | |
| Fenofibrate SCHEMBL21758490 | 0.99 | PPARA (0.97) | PPARACNR1CYP1A2CYP3A4PPARG | |
| Fenofibrate SCHEMBL29262793 | 0.99 | PPARA (0.97) | PPARACNR1CYP1A2CYP3A4PPARG | |
| Fenofibrate SCHEMBL27847067 | 0.99 | PPARA (0.97) | PPARACNR1CYP1A2CYP3A4PPARG | |
| Fenofibrate SCHEMBL22209064 | 0.99 | PPARA (0.97) | PPARACNR1CYP1A2CYP3A4PPARG | |
| SCHEMBL31084128 | 0.96 | PPARA (0.92) | PPARACNR1CYP1A2CYP3A4PPARG | |
| SCHEMBL31084127 | 0.96 | PPARA (0.92) | PPARACNR1CYP1A2CYP3A4PPARG | |
| SCHEMBL21992457 | 0.93 | CNR1 (0.86) | PPARACNR1CYP1A2CYP3A4PPARG | |
| Fenofibrate SCHEMBL4251589 | 0.92 | PPARA (0.85) | PPARACNR1CYP1A2CYP3A4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192259-A1 | SYNERGY FOR INCREASING INSULIN SENSITIVITY | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2021150958-A1 | TREATMENT METHODS USING A COMBINATION OF PANTETHINE AND A VANIN AGONIST | SCHELLING D CHRISTOPHER (US) | 2021-07-29 | — | — | WO | disclosed |
| US-9173847-B2 | Tablet comprising a fibrate | VELOXIS PHARMACEUTICALS A/S (DK) | 2015-11-03 | — | — | US | disclosed |
| CN-103284952-A | Medical composition containing fenofibrate | BEIJING WINSUNNY PHARMACEUTICAL CO LTD | 2013-09-11 | — | — | CN | disclosed |
| US-20090074872-A1 | Active Agent Formulations, Methods of Making, and Methods of Use | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| CN-101217951-A | Formulations containing fenofibrate and a surfactant mixture | TEVA PHARMA (IL) | 2008-07-09 | — | — | CN | disclosed |
| US-7374779-B2 | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents | LIPOCINE, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1429729-A4 | COMBINATION DOSAGE FORM CONTAINING A CHOLESTEROL -LOWERING AGENT , AN INHIBITOR OF THE RENIN-ANGIOTENSIN, AND ASPIRIN | LONGWOOD PHARMACEUTICAL RES IN (US) | 2007-07-04 | — | — | EP | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| US-20070026062-A1 | Tablet comprising a fibrate | LIFECYCLE PHARMA A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| EP-1429729-A1 | COMBINATION DOSAGE FORM CONTAINING A CHOLESTEROL -LOWERING AGENT , AN INHIBITOR OF THE RENIN-ANGIOTENSIN, AND ASPIRIN | Longwood Pharmaceutical Research, Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6669955-B2 | In unit dose appropriate for once-daily dosing, wherein at least one of active agents is contained in dosage unit within dosage form that physically separates it from other active agents | LONGWOOD PHARMACEUTICAL RESEARCH, INC. | 2003-12-30 | — | — | US | disclosed |
| US-6576256-B2 | Cholesterol-lowering agent, such as an HMG CoA reductase inhibitor; an inhibitor of the renin-angiotensin system, such as an ACE inhibitor; aspirin; and optionally one or more of vitamin B6, vitamin B12, and folic acid. | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030077297-A1 | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents | LIPOCINE, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20030068366-A1 | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-04-10 | — | — | US | disclosed |
| WO-2003020243-A1 | COMBINATION DOSAGE FORM CONTAINING A CHOLESTEROL -LOWERING AGENT , AN INHIBITOR OF THE RENIN-ANGIOTENSIN, AND ASPIRIN | LONGWOOD PHARMACEUTICAL RESEARCH, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20030049314-A1 | TREATMENT OF PATIENTS AT ELEVATED CARDIOVASCULAR RISK WITH A COMBINATION OF A CHOLESTEROL-LOWERING AGENT, AN INHIBITOR OF THE RENIN-ANGIOTENSIN SYSTEM, AND ASPIRIN | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2003-03-13 | — | — | US | disclosed |
| WO-2000069446-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069445-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| US-6074670-A | INERT HYDROSOLUBLE CARRIER COVERED WITH AT LEAST ONE LAYER CONTAINING FENOFIBRATE IN A MICRONIZED FORM; HYDROPHILIC POLYMER AND A SURFACTANT | LABORATOIRES FOURNIER, S.A. (FR) | 2000-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070026062-A1 | Tablet comprising a fibrate | FFAR4, FFAR2, PPARD | PPARA 4/4885CNR1 1122/4885CYP1A2 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.